BiotechTube

Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory Chronic Lymphocytic Leukemia

Conditions

Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Trial Timeline

Nov 25, 2020 → Feb 1, 2028

NCT ID
NCT04623541

About Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab

Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab is a phase 1/2 stage product being developed by Eli Lilly for Relapsed/Refractory Chronic Lymphocytic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT04623541. Target conditions include Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome.

What happened to similar drugs?

0 of 10 similar drugs in Relapsed/Refractory Chronic Lymphocytic Leukemia were approved

Approved (0) Terminated (1) Active (9)
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
❌Blinatumomab + Standard of Care ChemotherapyAmgenPhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + BendamustineGilead SciencesPhase 3
🔄Odronextamab + Lenalidomide + RituximabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04623541Phase 1/2Active

Competing Products

20 competing products in Relapsed/Refractory Chronic Lymphocytic Leukemia

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2416ModernaPhase 2
0
agenT-797MiNK TherapeuticsPhase 1
19
Valemetostat TosylateDaiichi SankyoPhase 2
39
Eribulin mesylateEisaiPhase 2
35
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
ISB 1342Glenmark PharmaceuticalsPhase 1
29
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
47
Linperlisib ； RituximabJiangsu Hengrui MedicinePhase 1/2
39
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
42
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
40
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
29
Venetoclax + DexamethasoneAbbViePhase 1/2
32
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
AZD4573AstraZenecaPhase 2
35
Moxetumomab PasudotoxAstraZenecaPre-clinical
26
Administration of AZD6738AstraZenecaPhase 1
29